Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 26.83
NAS:SRPT's Cash-to-Debt is ranked lower than
51% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:SRPT: 26.83 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SRPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.29  Med: 5086.22 Max: No Debt
Current: 26.83
Equity-to-Asset 0.84
NAS:SRPT's Equity-to-Asset is ranked higher than
74% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:SRPT: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SRPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.09  Med: 0.88 Max: 0.98
Current: 0.84
-0.09
0.98
Debt-to-Equity 0.03
NAS:SRPT's Debt-to-Equity is ranked higher than
89% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:SRPT: 0.03 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SRPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.68  Med: 0.08 Max: 2.07
Current: 0.03
-0.68
2.07
Piotroski F-Score: 4
Altman Z-Score: 20.63
Beneish M-Score: 36.80
WACC vs ROIC
14.61%
-545.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -435.96
NAS:SRPT's Operating Margin % is ranked lower than
79% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:SRPT: -435.96 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SRPT' s Operating Margin % Range Over the Past 10 Years
Min: -17572.55  Med: -215.28 Max: -71.16
Current: -435.96
-17572.55
-71.16
Net Margin % -218.67
NAS:SRPT's Net Margin % is ranked lower than
71% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:SRPT: -218.67 )
Ranked among companies with meaningful Net Margin % only.
NAS:SRPT' s Net Margin % Range Over the Past 10 Years
Min: -17560.26  Med: -286.12 Max: -4.93
Current: -218.67
-17560.26
-4.93
ROE % -37.09
NAS:SRPT's ROE % is ranked lower than
53% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:SRPT: -37.09 )
Ranked among companies with meaningful ROE % only.
NAS:SRPT' s ROE % Range Over the Past 10 Years
Min: -309.2  Med: -100.95 Max: -16.44
Current: -37.09
-309.2
-16.44
ROA % -29.88
NAS:SRPT's ROA % is ranked lower than
53% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:SRPT: -29.88 )
Ranked among companies with meaningful ROA % only.
NAS:SRPT' s ROA % Range Over the Past 10 Years
Min: -93.53  Med: -64.53 Max: -4.62
Current: -29.88
-93.53
-4.62
ROC (Joel Greenblatt) % -547.61
NAS:SRPT's ROC (Joel Greenblatt) % is ranked lower than
56% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:SRPT: -547.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SRPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -978.9  Med: -575.45 Max: -309.3
Current: -547.61
-978.9
-309.3
3-Year Revenue Growth Rate -35.80
NAS:SRPT's 3-Year Revenue Growth Rate is ranked lower than
81% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:SRPT: -35.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SRPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -73.3  Med: 7.45 Max: 343.4
Current: -35.8
-73.3
343.4
3-Year EBITDA Growth Rate 26.80
NAS:SRPT's 3-Year EBITDA Growth Rate is ranked higher than
78% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:SRPT: 26.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SRPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -36.3  Med: 3.05 Max: 62.1
Current: 26.8
-36.3
62.1
3-Year EPS without NRI Growth Rate 18.40
NAS:SRPT's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:SRPT: 18.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SRPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62.2  Med: 0.2 Max: 213.5
Current: 18.4
-62.2
213.5
GuruFocus has detected 3 Warning Signs with Sarepta Therapeutics Inc $NAS:SRPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SRPT's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SRPT Guru Trades in Q3 2016

Louis Moore Bacon 70,000 sh (New)
Paul Tudor Jones 215,933 sh (New)
Steven Cohen 3,284,287 sh (+19.53%)
First Eagle Investment 300 sh (unchged)
Steven Cohen 250,000 sh (unchged)
Columbia Wanger Sold Out
» More
Q4 2016

SRPT Guru Trades in Q4 2016

Jim Simons 49,078 sh (New)
First Eagle Investment 300 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen 1,367,599 sh (-58.36%)
» More
Q1 2017

SRPT Guru Trades in Q1 2017

Paul Tudor Jones 80,929 sh (New)
John Paulson 78,101 sh (New)
Jim Simons 86,078 sh (+75.39%)
Louis Moore Bacon Sold Out
Steven Cohen 803,300 sh (-41.26%)
» More
Q2 2017

SRPT Guru Trades in Q2 2017

Steven Cohen 2,025,406 sh (+152.14%)
John Paulson Sold Out
Jim Simons Sold Out
Paul Tudor Jones 27,517 sh (-66.00%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Sold Out 0.03%$28.41 - $36.72 $ 47.1045%0
John Paulson 2017-03-31 New Buy0.03%$27.67 - $37.89 $ 47.1052%78,101
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AVXS, NAS:LGND, NAS:ONCE, NAS:PTLA, NAS:AGIO, NAS:LOXO, NAS:BPMC, NAS:FOLD, NAS:HALO, NAS:SAGE, NAS:NKTR, NYSE:XON, NAS:RARE, NAS:INSM, NAS:FGEN, NAS:CORT, NAS:CLVS, NAS:ARRY, NAS:PBYI, NAS:RGEN » details
Traded in other countries:AB3A.Germany,
Headquarter Location:USA
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Ratios

vs
industry
vs
history
PB Ratio 6.57
SRPT's PB Ratio is ranked lower than
53% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. SRPT: 6.57 )
Ranked among companies with meaningful PB Ratio only.
SRPT' s PB Ratio Range Over the Past 10 Years
Min: 2  Med: 5.34 Max: 238.78
Current: 6.57
2
238.78
PS Ratio 43.94
SRPT's PS Ratio is ranked lower than
83% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. SRPT: 43.94 )
Ranked among companies with meaningful PS Ratio only.
SRPT' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 25.38 Max: 39930
Current: 43.94
1.56
39930
EV-to-EBIT -10.57
SRPT's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. SRPT: -10.57 )
Ranked among companies with meaningful EV-to-EBIT only.
SRPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.1  Med: -5.3 Max: -0.8
Current: -10.57
-29.1
-0.8
EV-to-EBITDA -10.84
SRPT's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. SRPT: -10.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.4  Med: -5.5 Max: -0.9
Current: -10.84
-30.4
-0.9
EV-to-Revenue 46.08
SRPT's EV-to-Revenue is ranked lower than
76% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. SRPT: 46.08 )
Ranked among companies with meaningful EV-to-Revenue only.
SRPT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 24.4 Max: 58632.1
Current: 46.08
0.8
58632.1
Current Ratio 5.92
SRPT's Current Ratio is ranked higher than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. SRPT: 5.92 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s Current Ratio Range Over the Past 10 Years
Min: 0.76  Med: 6.65 Max: 36.25
Current: 5.92
0.76
36.25
Quick Ratio 5.29
SRPT's Quick Ratio is ranked higher than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. SRPT: 5.29 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 6.63 Max: 36.25
Current: 5.29
0.76
36.25
Days Inventory 8.00
SRPT's Days Inventory is ranked higher than
90% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. SRPT: 8.00 )
Ranked among companies with meaningful Days Inventory only.
SRPT' s Days Inventory Range Over the Past 10 Years
Min: 8  Med: 17987.48 Max: 17987.48
Current: 8
8
17987.48
Days Sales Outstanding 108.41
SRPT's Days Sales Outstanding is ranked lower than
88% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. SRPT: 108.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.22  Med: 87.87 Max: 1158.5
Current: 108.41
28.22
1158.5
Days Payable 5.00
SRPT's Days Payable is ranked lower than
60% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. SRPT: 5.00 )
Ranked among companies with meaningful Days Payable only.
SRPT' s Days Payable Range Over the Past 10 Years
Min: 5  Med: 83360.38 Max: 83360.38
Current: 5
5
83360.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.20
SRPT's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. SRPT: -13.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.6  Med: -20.4 Max: -11.6
Current: -13.2
-27.6
-11.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.85
SRPT's Price-to-Net-Cash is ranked higher than
58% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. SRPT: 10.85 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRPT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.03  Med: 6.53 Max: 72.6
Current: 10.85
3.03
72.6
Price-to-Net-Current-Asset-Value 7.80
SRPT's Price-to-Net-Current-Asset-Value is ranked higher than
63% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. SRPT: 7.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRPT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.95  Med: 6.2 Max: 42
Current: 7.8
2.95
42
Price-to-Tangible-Book 6.71
SRPT's Price-to-Tangible-Book is ranked higher than
54% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SRPT: 6.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.41  Med: 4.88 Max: 395
Current: 6.71
2.41
395
Price-to-Median-PS-Value 1.73
SRPT's Price-to-Median-PS-Value is ranked lower than
92% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SRPT: 1.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 3.71 Max: 1070.33
Current: 1.73
0.08
1070.33
Earnings Yield (Greenblatt) % -9.46
SRPT's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. SRPT: -9.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -122.3  Med: -18.75 Max: -3.4
Current: -9.46
-122.3
-3.4

More Statistics

Revenue (TTM) (Mil) $56.77
EPS (TTM) $ -2.49
Beta2.07
Short Percentage of Float24.21%
52-Week Range $26.26 - 63.73
Shares Outstanding (Mil)64.33

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 300 357 546
EPS ($) -2.25 -1.67 0.97
EPS without NRI ($) -2.25 -1.67 0.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}